Sector Expert: Scott Jackson

Celator Pharmaceuticals Inc.

Image: Scott Jackson

Scott Jackson was appointed Celator's chief executive officer in April 2008. He joined Celator in October 2007 as head of commercial Development. Mr. Jackson has more than 23 years of experience in the pharmaceutical and biotechnology industry and has held positions of increasing responsibility in sales, marketing and commercial development at Eli Lilly & Co., SmithKline Beecham, ImClone Systems Inc., Centocor (now Janssen Biotech Inc.), Eximias Pharmaceuticals and YM BioSciences (acquired Eximias). Mr. Jackson holds a bachelor's degree in pharmacy from the Philadelphia College of Pharmacy and Science and a master's degree in business administration from the University of Notre Dame.



Recent Interviews

Celator's New Drug Combo Will Revolutionize AML Standard of Care: Scott Jackson and Lawrence Mayer (4/22/15)

Celator Pharmaceuticals Inc.'s remarkable drug combination strategy has produced a cancer-fighting duo endowed with a coveted fast-track designation. Scott Jackson, the company's CEO, and Lawrence Mayer, president, chief scientific officer and founder, tell The Life Sciences Report about what sets Celator apart, and reveal profit-generating milestones that investors should keep on their scopes.



Due to permission requirements, not all quotes are shown.